Description du projet
Aperçu de la physiopathologie des maladies rénales: la voie vers le pronostic
L’insuffisance rénale chronique (IRC) est associée à des lésions rénales qui entraînent la perte progressive de la fonction rénale. Les manifestations cliniques de l’IRC sont hétérogènes, et les thérapies et outils permettant de classer les patients sont limités. Collectivement, ces limitations nécessitent une meilleure compréhension des maladies rénales. Financé par le Conseil européen de la recherche, le projet TargetCKD a pour mission d’étudier les mécanismes cellulaires et moléculaires à l’origine de l’IRC. À partir d’échantillons de patients, les chercheurs souhaitent identifier les biomarqueurs associés à la maladie et les événements clés qui déterminent l’apparition de la maladie et sa progression vers l’insuffisance rénale. Les activités du projet devraient faciliter le développement de nouveaux outils de diagnostic et de prédiction ainsi que de stratégies thérapeutiques.
Objectif
Chronic Kidney Disease (CKD) represents an important medical, social and economic burden with high morbidity and mortality. The prevalence of CKD has reached >10% in the developed world, and CKD globally accounts for more years lived with disability than all neoplasms combined. Therapeutic strategies to treat CKD or tools for risk stratification of patients are limited and the field has produced the fewest translational randomized clinical trials in medicine while diagnosis is still based on invasive tissue biopsies. TargetCKD aims to establish a holistic understanding of cellular and molecular mechanisms that drive disease to develop novel diagnostic, predictive and therapeutic options. Concrete objectives are: (1) the development of a platform for identification of novel predictive markers and therapeutic targets in kidney biopsies; (2) the identification of conserved spatio-temporal mechanisms and cellular cross-talk events driving CKD; (3) the validation of mechanisms and therapeutic targets in human 3D organoid systems and development of therapeutics and (4) the development of a noninvasive diagnostic platform from urine. TargetCKD will utilize a broad interdisciplinary expertise with various novel single cell and spatial genomic and computational technologies combined with transgenic mouse models and cutting-edge in vitro platforms. The integration of all these technologies in clinical relevant specimen with follow up data and large independent validation cohorts will allow TargetCKD to radically transform nephrology towards a better understanding of kidney diseases, development of novel diagnostics and risk stratification tools for patient allocation and clinical testing as well as urgently needed therapeutics for patients suffering from CKD. The passion that drives this project results from a simple emerging hypothesis: It is possible to predict CKD and develop therapeutics by an in-depth systems approach utilizing emerging genomic technologies.
Mots‑clés
Programme(s)
- HORIZON.1.1 - European Research Council (ERC) Main Programme
Régime de financement
HORIZON-ERC - HORIZON ERC GrantsInstitution d’accueil
52074 Aachen
Allemagne